The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences.

The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences.

The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences.

The Canadian Generic Pharmaceutical Association (CGPA) is launching its “Myth vs. Reality” campaign on LinkedIn and Facebook, aimed at debunking myths about the generic pharmaceutical industry and informing Quebeckers, key industry players and Quebec policymakers about the value of generic prescription medicines.